Table 1.
Completeness and standard items
| Esophageal carcinoma | Gastric carcinoma | |||||||
|---|---|---|---|---|---|---|---|---|
| Reference N = 1367 | NR N = 685 (%) | SSR N = 806 (%) | p value**** | Reference N = 1012 | NR N = 463 (%) | SSR N = 505 (%) | p value**** | |
| Overall completeness | 666 (48.7) | 450 (65.7) | 789 (97.9) | < 0.01 | 349 (34.5) | 197 (42.5) | 483 (95.6) | < 0.01 |
| T stage | 1338 (97.9) | 678 (99.0) | 804 (99.8) | 0.09 | 1007 (99.5) | 459 (99.1) | 505 (100) | 0.05 |
| Number of lymph nodes* | 1365 (99.9) | 685 (100) | 806 (100) | – | 1005 (99.3) | 459 (99.1) | 505 (100) | 0.05 |
| Histology type** | 855 (97.9) | 391 (97.5) | 276 (100) | 0.01 | 929 (98.5) | 412 (99.0) | 416 (99.8) | 0.22 |
| Subtype of AC1 | 315 (36.8) | 194 (49.6) | 149 (54.0) | 0.27 | 668 (71.9) | 327 (79.4) | 399 (95.9) | < 0.01 |
| Differentiation grade*** | 159 (72.3) | 122 (84.1) | 119 (97.5) | < 0.01 | 214 (81.7) | 125 (89.3) | 206 (100) | < 0.01 |
AC, adenocarcinoma
*Only “number of lymph nodes” are reported, since the “number of positive lymph nodes” resulted in exactly the same numbers
**Excluded were reports describing T0 and Tis carcinomas and subtotal regression after neoadjuvant therapy
***Included were reports describing squamous cell carcinoma or adenocarcinoma intestinal type
****NR versus SSR